Diosmin plus cabergoline for prevention of Ovarian Hyperstimulation Syndrome in high-risk women undergoing intracytoplasmic sperm injection (ICSI)

This study is testing whether adding a medication called Diosmin — usually used to treat vein problems — to standard treatment can help prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing fertility treatment (ICSI). OHSS is a potentially serious complication of fertility treatment where the ovaries become swollen and painful. Women at high risk of OHSS will be randomly assigned to receive either Diosmin plus cabergoline, or cabergoline alone. You may be eligible if: - You are a woman between 23 and 48 years old - You are undergoing intracytoplasmic sperm injection (ICSI) fertility treatment - You have signs of being at high risk for OHSS (more than 20 follicles on ultrasound, high estrogen level, or more than 15 eggs retrieved) - You have infertility, with or without polycystic ovary syndrome (PCOS) You may NOT be eligible if: - There are no listed exclusion criteria for this study Talk to your doctor about whether this trial might be right for you.